Drug Profile

CVN 293

Alternative Names: CVN-293

Latest Information Update: 28 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cerevance
Class Anti-inflammatories; Antidementias; Small molecules
Mechanism of Action KCNK13 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Neurodegenerative disorders
Preclinical Amyotrophic lateral sclerosis

Most Recent Events

08 Apr 2025 Adverse events and efficacy data from a phase I trial (In volunteers) released by Cerevance
05 Apr 2025 Updated adverse events and pharmacodynamics data from a phase I trial (In volunteers) presented at the 77th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)
18 Nov 2024 Cerevance plans a phase-II trial for Frontotemporal dementia

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com